The use of high doses of OROS hydromorphone in an acute palliative care unit.
Summary of "The use of high doses of OROS hydromorphone in an acute palliative care unit."
Abstract Objectives: To characterize patients who received high doses of OROS hydromorphone (OROD-HY), a retrospective study of patients admitted in an acute pain relief and palliative care unit for a period of two years (from June 2009 to June 2011) was performed. Methods: Globally, 79 patients were prescribed OROS-HY during admission at mean maximum doses of 68?mg/day (?42). Twenty-two patients were switched from other opioids to OROS-HY and 16 patients were switched from OROS-HY to other opioids. Sixty-three patients were discharged home with a prescription of OROS-HY with doses of 53?mg/day (?44). Doses were significantly lower in older patients (p?0.005). The mean admission time was 6.1 days (?3.2). During admission 10 patients (12.6%) were prescribed doses of OROS-HY of more than 64?mg/day. Results: The maximum mean doses of this group of patients reached during admission were 238?mg/day. Eight of them were successfully treated and discharged home with doses of 175?mg/day. Two patients did not achieve an adequate balance between analgesia and adverse effects and received alternative treatments. Conclusion: This study demonstrated that OROS-HY administered in larger doses was relatively safe and effective, showing versatility and flexibility similar to other opioids.
This article was published in the following journal.
Name: Current medical research and opinion
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22077957
- DOI: http://dx.doi.org/10.1185/03007995.2011.628982
Medical and Biotech [MESH] Definitions
Coronary Care Units
The hospital unit in which patients with acute cardiac disorders receive intensive care.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
An acronym for Acute Physiology and Chronic Health Evaluation, a scoring system using routinely collected data and providing an accurate, objective description for a broad range of intensive care unit admissions, measuring severity of illness in critically ill patients.
Rapidly decreasing response to a drug or physiologically active agent after administration of a few doses. In immunology, it is the rapid immunization against the effect of toxic doses of an extract or serum by previous injection of small doses. (Dorland, 28th ed)
Facilities or services which are especially devoted to providing palliative and supportive care to the patient with a terminal illness and to the patient's family.
OBJECTIVE: To determine the effect of a lower starting dose of OROS® hydromorphone compared with a higher starting dose. DESIGN: Data from the first 15 days of treatment were compared in a combined a...
Objective: Opioids are recommended for patients with moderate to severe pain due to osteoarthritis (OA), who do not receive adequate analgesia from nonopioid treatment. The objective of this study...
INTRODUCTION: Strong opioids are efficient drugs for treating chronic pain. In cancer patients, strong opioids are the mainstay of pain management, but in non-cancer pain caution is advised due to pos...
A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008) was performed. A total of 212 patients were prescribed at discharge CRO for...
Abstract Despite the favorable effects reported with opioid switching performed in a specialized unit in the short term, data on long-term basis are poor, particularly after discharging patients hom...
The purpose of this study was to characterize a safe and effective means of conversion and titration to an appropriate dose of hydromorphone HCI, to demonstrate comparable efficacy of OROS...
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone in patients with chronic non-malignant pain convertin...
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone HCI (slow release) in patients with chronic cancer pa...
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl), a once daily opioid analgesic that can relieve pain. A large number of clinical studies have been...